Takeda Sees FY2021 as Inflection Year for Pipeline, 4 Potential Approvals from 6 Submission-Planned Assets

Takeda CEO Christophe Weber Takeda Pharmaceutical is poised to make regulatory submissions for up to six new molecular entities (NMEs) in FY2021, with the potential for up to four approvals by the end of that year, CEO Christophe Weber said...read more